A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418

Key facts

Sponsor

1ST Biotherapeutics, Inc.

Principal Investigator

1STBIO study manager

1ST Biotherapeutics, Inc.

Intervention

FB418(drug)

Enrollment

64 enrolled

Eligibility

19 years · All sexes

Timeline

2023 – 2024

Study locations (1)

• Seoul National University, Seoul, South Korea

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Amyotrophic Lateral Sclerosis (ALS)

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1, PHASE2NCT07017946
  Intestinal Microbiome Transplant in ALS
  Duke University
• ENROLLING BY INVITATIONNANCT07539662
  Unrelated Umbilical Cord Blood Transplantation for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
  Institute of Hematology & Blood Diseases Hospital, China
• RECRUITINGPHASE1, PHASE2NCT07287397
  Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS
  Vector Y Therapeutics
• ACTIVE NOT RECRUITINGPHASE2NCT07023835
  Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
  Zydus Therapeutics Inc.
• RECRUITINGNANCT07413718
  Inspiratory Muscle Training in Amiotrophyc Lateral Sclerosis
  University Ramon Llull
• RECRUITINGPHASE1NCT06665165
  AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis
  Amylyx Pharmaceuticals Inc.
• RECRUITINGNANCT06609213
  Oral Intake of Enteral Nutrition Formula Preceding Placement and Feeding Via GTube and Its Impact on Formula Intolerance in pALS
  Andrea Charvet
• RECRUITINGNANCT06249412
  The Importance of Positive Expiratory Pressure Associated With the In-exsufflator in ALS Patients
  Groupe Hospitalier du Havre

See all trials for Amyotrophic Lateral Sclerosis (ALS) →